EMAConflict of interest?In 2016, PharmaMar filed a European marketing authorisation application for Aplidin as a treatment for patients with multiple myeloma. After the European Medicines Agency rejected the MAA twice, which … more ➔
Analyst commentBiotech funding environment calls for more...From its all-time high in August 2021 the largest and most important index for the biotech industry also in Europe (NBI) lost around 25%. After a period of excessive capital inflows, money is much harder … more ➔
StatementBiomanufacturing: Step up and speak up In a world where biotechnology has been enabling products and processes for decades, it’s time to step out from behind the technology and claim the resulting products and their value in our everyday … more ➔
Analyst commentHave biotech stocks bottomed out?Biotechnology was dramatically rewarded in the financial markets through much of 2020 and the first half of 2021, widely credited for providing the COVID-19 vaccines. This followed four already exceptional … more ➔
StatementWhy we need the switch from oil to biotech...Our species – modern humans, or homo sapiens sapiens – has ever striven for progress. And progress was greatly enabled by fire, a fundamental chemical phenomenon that allows the fast release of large … more ➔
Analyst commentHealth: still a defensive position in por...Healthcare has long been considered one of the most reliable defensive sectors – an effective portfolio buffer when equity markets turn volatile. That’s because hospitals, drug makers, medical device … more ➔
StatementBiotechnology-driven carbon revolution Fossil carbon is in nearly everything we use in our daily lives ranging from power and fuels to fibers, coatings, and materials used in our clothes, packaging, toys, and household goods. Virgin fossil … more ➔
The silent pandemic is not silent anymore COVID-19 is the acute pandemic, while antimicrobial resistance (AMR) is a silent, pandemic. New data makes the AMR pandemic visible, with the first global study of AMR estimating that 1.27 million people … more ➔
After the setback, what's next for bi... While the Nasdaq Biotechnology index saw a huge uplift during the pandemic (+ 77% since March 2020 until reaching a peak in August 2021), it lost 27% during the last six months vs a 11%/4% decline for … more ➔
BiologisationThe Next Big Thing: “Biologisation&#... The development of a sustainable bio-based economy will lead to disruptive economic changes. Venture capitalists focused on targets to drive digitisation in the past are now moving their attention to … more ➔
